

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Gaush Meditech Ltd**  
**高视医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2407)**

## **INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025**

### **INTERIM RESULTS HIGHLIGHTS**

Revenue of the Group was RMB653.1 million for the six months ended June 30, 2025, representing an increase of 1.7% as compared to the revenue of RMB642.0 million in the same period in 2024.

Net profit of the Group was RMB35.9 million for the six months ended June 30, 2025, representing an increase of 33.5% as compared to the net profit of RMB26.9 million recorded in the same period in 2024.

The Group's basic earnings per Share was RMB0.26 for the six months ended June 30, 2025 as compared to the basic earnings per Share of RMB0.19 in the same period in 2024.

The Group's research and development expenses for the six months ended June 30, 2025 were RMB43.4 million, representing an increase of 23.6% as compared to the research and development expenses of RMB35.1 million in the same period in 2024. The Group's research and development expenses amounted to 5.5% and 6.6% of the revenue, and 19.7% and 21.4% of the revenue of the Proprietary Products for the six months ended June 30, 2024 and 2025, respectively, both remaining at a relatively stable and high level.

The Board did not recommend the payment of an interim dividend for the six months ended June 30, 2025 (six months ended June 30, 2024: Nil).

**SUMMARY OF UNAUDITED CONDENSED CONSOLIDATED STATEMENT  
OF PROFIT OR LOSS**

	<b>For the six months ended June 30,</b>	
	<b>2025</b>	<b>2024</b>
	<b>(RMB'000)</b>	<b>(RMB'000)</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
<b>REVENUE</b>		
Cost of sales	<b>653,081</b>	642,034
	<b>(337,417)</b>	<b>(343,681)</b>
<b>Gross profit</b>	<b>315,664</b>	298,353
Other income and gains	<b>14,689</b>	16,824
Selling and distribution expenses	<b>(115,593)</b>	<b>(115,475)</b>
Administrative expenses	<b>(85,277)</b>	<b>(73,608)</b>
Finance costs	<b>(10,549)</b>	<b>(20,603)</b>
Research and development expenses	<b>(43,400)</b>	<b>(35,140)</b>
Other expenses	<b>(8,178)</b>	<b>(11,956)</b>
<b>PROFIT BEFORE TAX</b>	<b>67,356</b>	58,395
Income tax expenses	<b>(31,462)</b>	<b>(31,467)</b>
<b>PROFIT FOR THE PERIOD</b>	<b>35,894</b>	<b>26,928</b>

## MANAGEMENT DISCUSSION AND ANALYSIS

### BUSINESS OVERVIEW

The Group is principally engaged in the R&D, production and distribution of a broad spectrum of ophthalmic medical equipment and consumables, and the provision of ancillary technical services to end customers. As of the date of this announcement, the Group has a “Global 4+2” R&D layout, with several R&D and production platforms in four cities in the PRC, namely Shenzhen, Suzhou, Wuxi and Wenzhou, and two R&D and production platforms overseas in the Netherlands and Germany. At the same time, the Group has a sales network covering 51 countries and regions around the world, and has 135 engineers in Greater China which makes the Group capable of providing 7\*24 hours technical support services for its equipment.

As of June 30, 2025, the Group: (i) had a product portfolio of 165 products in total, including 72 Proprietary Products, further enriching the portfolio of the Proprietary Products; (ii) co-operated with 19 overseas brand partners, of which 15 had entered into exclusive distribution arrangements with the Group in respect of their products, including Heidelberg, Quantel Medical, Schwind and Optos; (iii) had its products sold to 51 countries and regions worldwide, and had served approximately 6,000 end customers in Greater China during the Reporting Period; and (iv) continued to invest in R&D and achieved a number of significant progress. For instance, the Company has officially obtained product registration certificates for the corneal confocal microscopes T3-600 and T3-400 developed in-house in April 2025; and the Company’s ocular fundus cameras developed in-house were formally approved for marketing in June 2025. In addition, the Company has also completed the product registration process and obtained registration certificates for the intraocular lens implant system developed in-house in May 2025 and for frequency-domain biometer developed in-house in August 2025, which further enriched the Group’s Proprietary Products line, and also signified the further consolidation of R&D, the overall process and the production capability of Gaush.

### Products of the Group

As of June 30, 2025, the Group had a product portfolio of 165 products in total, which included the Proprietary Products, being products developed and manufactured by the Group, and the Distribution Products, being the products of the Group’s brand partners, and consisted of diagnostic equipment, treatment and surgical instrument, high-value consumables and general consumables. The Group’s product portfolio covers seven major ophthalmology sub-specialties where ophthalmic medical devices are utilized for their diagnosis, treatment or surgery, being the vitreoretinal diseases, cataracts, refractive surgery, glaucoma, ocular surface diseases, optometry and pediatric ophthalmology, which enables the Group to provide the customers with integrated product and service offering.

## **Proprietary Products**

As a result of its “Global 4+2” R&D layout and continuous investment in R&D, the Group’s portfolio of Proprietary Products continued to expand, mainly including intraocular lens, ophthalmic scalpel products and ophthalmic examination equipment. As of June 30, 2025, the revenue contribution of the Group’s Proprietary Products amounted to RMB203.0 million, accounting for 38.3% of the Group’s revenue from sales of products, representing an increase as compared with the ratio of revenue contribution of the Proprietary Products to the Group’s revenue from sales of products of 33.6% in the first half of 2024. As of June 30, 2025, the revenue contribution of the Group’s intraocular lens under the Proprietary Products amounted to RMB170.5 million, representing a year-on-year increase of 11.4%, which was mainly due to the positive impact of the expanded customer coverage and usage resulted from the implementation of national procurement policy for intraocular lens on the performance, as well as the steady growth of the overseas intraocular lens business.

## **Distribution Products**

As of June 30, 2025, the Group had co-operated with 19 overseas brand partners, 15 of which had entered into exclusive distribution arrangements with the Group, including Heidelberg, Quantel Medical, Schwind and Optos. As of June 30, 2025, the revenue contribution of the Group’s Distribution Products amounted to RMB327.1 million, representing a year-on-year decrease of 6.8%.

## **Technical Services Business**

The Group has strong technical service capability. As of June 30, 2025, the Group has a technical service team comprising 135 technicians in Greater China. The Group sets up 13 technical service centers in Greater China, including one in Hong Kong, and has a technical service network covering all provincial administrative regions in China to provide 7\*24 hours technical services, ensuring the Group provides services to the customers in a timely manner. During the Reporting Period, the Group’s technical service team in Greater China had a total number of nearly 14,000 service visits. The technical service presents a great opportunity for the Group to interact with its customers, build brand loyalty and gain first-hand insights into market demand and unmet market needs. As of June 30, 2025, the revenue contribution of the Group’s technical services amounted to RMB119.1 million, representing a year-on-year increase of 8.3%.

## The Group's R&D Line-up

As of June 30, 2025, the Group had already possessed a “Global 4+2” R&D layout through organic growth and acquisitions and had a total of 252 R&D and production personnel, accounting for approximately 28.0% of the total headcount. The Group’s domestic R&D and production bases are located in four cities, namely Shenzhen, Suzhou, Wuxi and Wenzhou, and its overseas R&D and production bases are located in the Netherlands and Germany. The Group has made significant investments in the R&D of intraocular lens and OK-Lens, ophthalmic surgical equipment and supporting consumables, ophthalmic electrophysiological equipment and ancillary consumables, ophthalmic scalpels, optometry equipment, and diagnostic devices for dry eyes. During the Reporting Period, the Group’s research and development expenses amounted to RMB43.4 million, representing a year-on-year increase of 23.6% and accounting for 21.4% of the revenue from Proprietary Products, which was mainly due to the continuous increasing investment of the Group in R&D projects to strengthen its independent innovation capabilities to ensure the competitiveness of mid-to-long-term development in close alignment with the national strategic deployment.

**Shenzhen Base:** It mainly focuses on the layout of products such as domestic intraocular lens, myopic intraocular lens, ophthalmic electrophysiological equipment and fundus phacoemulsification and vitrectomy surgical equipment and intraoperative consumables. In particular, the Company has obtained a product registration certificate for an intraocular lens implant system in May 2025, and subsequently, the R&D and registration for mono-focal enhanced intraocular lens and ultrasonic phacoemulsification and vitrectomy equipment will continue to be promoted at the same time as focusing on the mass production of the approved products. In addition, the process validation of myopic intraocular lens has been in progress; the mono-focal enhanced intraocular lens has entered the stage of registration testing; the ophthalmic electrophysiological equipment has entered the stage of NMPA technical appraisal and is expected to obtain the product registration certificate in the second half of 2025; and the development of the ultrasonic phacoemulsification and vitrectomy system, fluid collection cartridge, vitrectomy probe and phacoemulsification handpiece is progressing smoothly, with prototype for registration completed. A product development partnership for electrophysiological corneal electrodes has been established with Fabrinal, a Swiss company, with contracts signed and work proceeding in an orderly manner.

**Suzhou Base:** It consists of two R&D and production platforms, mainly focusing on the layout of products such as OK-Lens, RGP and ophthalmic scalpels, among which, our independently developed and produced OK-lenses have entered the stage of registration testing. It is expected to receive the product registration certificate of the OK-Lens by the end of 2025 or early 2026. The defocusing lenses have been launched for sale, synchronized with the real-world research. Moving forward, the R&D and production in the fields of optometry and refraction will continue to be promoted.

**Wenzhou Base:** It has product registration certificates for the self-developed fundus photographic imaging machines, digital slit lamp microscopes, contrast sensitivity detectors, retinal vision testers and corneal topography. During the Reporting Period, it mainly focused on the R&D of two products, namely corneal topography and detector for dry eye. Both equipment are under smooth development and expected to complete product registration and launch in the first quarter of 2026.

**Wuxi Base:** Mainly focusing on the localization of own-brand diagnostic equipment, surgical equipment and consumables. Our self-developed corneal confocal microscopes T3-600 and T3-400 successfully obtained product registration certificates in April 2025. The fundus camera obtained its medical device registration certificate in June 2025 and has been officially launched for sale. Our frequency-domain biometer developed in-house successfully obtained its product registration certificate in August 2025.

### **Expansion of the Group's Distribution Products**

Leveraging the Group's nationwide multi-channel sales network and a well-established ophthalmology KOL network, as well as the professional sales team, the Group helps the customers evaluate their clinical needs, application environment and technical capabilities, thereby offering products that best suit their needs and circumstances and creating value for the customers. During the Reporting Period, the Group co-operated with 19 overseas brand partners, of which 15 had entered into exclusive distribution arrangements with the Group to distribute their products, including Heidelberg, Quantel Medical, Schwind and Optos. In addition, the existing upstream partners have also been continuously advancing their R&D or iterative computing upgrades and gradually launching new products to further enrich the Group's Distribution Products portfolio.

### **Overseas Business Expansion**

During the Reporting Period, the Company actively hosted an extensive array of on-site exhibitions and summits around the world. Distributors from different countries and regions and over 100 KOLs attended these summits. Furthermore, the Company also participated in several large on-site exhibitions with over 5,000 participants. In terms of R&D and production, the R&D of a new series of overseas intraocular lenses is currently progressing smoothly. In the meantime, the Company actively and vigorously promotes the registration of products in new countries and regions to expand a wider market presence. In particular, Teleon Surgical B.V., a wholly-owned subsidiary of the Company, has completed the design of the self-developed intraocular lens product, the Lentis Quantum Toric. The product has successfully passed a process validation with favorable results, and we anticipate to submit the registration application by the end of 2025.

The Group has sold products of Teleon to 51 countries and regions and sold products of Roland to 35 countries and regions.

## **Long-term Strategies and Outlook**

Adhering to the mission of “Technology Creates Bright Vision”, the Group has been persistently implementing the two-pronged approach of “Proprietary Products + high-end imports” and the internationalization development strategy, constantly improving and enriching its product line-up, and striving to become a leader of the global ophthalmic medical device industry. Based on this goal, the Group will:

- I. continuously increase investment in R&D, especially in major innovations in high-end ophthalmic medical devices, adhere to the domestic layout and the efficient commercialization process, further optimize the structures of product and revenue, and increase the proportion of revenue contribution from the Proprietary Products;
- II. keep unleashing the potential of existing products, maintain the leading position of diagnostic inspection products in the market, prioritize and increase investment in surgical treatment products, especially focusing on the development of surgical device-related consumables and independent implant consumables;
- III. continue to consolidate the platform advantages of the product portfolio fully covering the major sub-specialties of ophthalmology, and continuously improve and diversify its product portfolio through a combination of internal R&D, investment and acquisitions, introductions and collaborations;
- IV. continue to strengthen domestic and international market development, with a particular focus on promotion in local markets of China and Europe, while extending coverage to other international markets. Further expand the global sales network through in-house team building and channel acquisitions, thereby enhancing international coverage systematically and increasing the proportion of overseas revenue steadily; and
- V. continue to enhance management capabilities and improve its operational efficiency, strengthen talent recruitment and cultivation, improve personnel organization structure, compensation and performance appraisal systems and assessment and incentive mechanisms on an on-going basis, build a high-quality talent pool, and practice the Group’s core values.

## FINANCIAL REVIEW

### Revenue

During the Reporting Period, the Group mainly generated its revenue from (i) sales of products, including ophthalmic medical equipment and consumables; and (ii) provision of technical services.

The Group's revenue increased by 1.7% from RMB642.0 million for the six months ended June 30, 2024 to RMB653.1 million for the six months ended June 30, 2025. Amidst the ongoing global economic downturn, the Group's revenue has managed to maintain a certain level of growth, mainly due to the synergistic effects of overseas market expansion and growth in revenue from the Proprietary Products.

The table below sets forth the breakdown of sales revenue from the products of the Group by Distribution Products and Proprietary Products for the periods indicated:

	<b>For the six months ended June 30,</b>	
	<b>2025</b> <i>(RMB'000)</i>	<b>2024</b> <i>(RMB'000)</i>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Distribution Products	<b>327,143</b>	351,048
Proprietary Products	<b>203,008</b>	178,005
<b>Total</b>	<b><u>530,151</u></b>	<b><u>529,053</u></b>

### Gross Profit and Gross Profit Margin

The Group's gross profit increased by 5.8% from RMB298.4 million for the six months ended June 30, 2024 to RMB315.7 million for the six months ended June 30, 2025. The Group's gross profit margin increased from 46.5% for the six months ended June 30, 2024 to 48.3% for the six months ended June 30, 2025. Such increase was mainly due to (i) the changes in the Group's sales product mix, with the ophthalmic medical consumables with a higher consolidated profit margin recording an increase in the proportion of sales; and (ii) benefiting from the Group's accumulated technical support and after-sales maintenance experience, the sales of technical services have continued to increase, further boosting gross profit margin.

## **Other Income and Gains**

During the Reporting Period, the Group's other income and gains primarily consisted of (i) bank interest income; (ii) government grants; and (iii) investment income and fair value gains from financial products at fair value through profit or loss.

The Group's other income and gains decreased by 12.5% from RMB16.8 million for the six months ended June 30, 2024 to RMB14.7 million for the six months ended June 30, 2025. Such decrease was mainly attributable to the reduction of the Group's income generated from government grants as compared with the same period of last year.

## **Selling and Distribution Expenses**

During the Reporting Period, the Group's selling and distribution expenses primarily consisted of (i) salaries and remuneration of the Group's sales and marketing personnel; (ii) marketing expenses for organizing marketing events and promotion of the Group's products; and (iii) transportation and travel expenses incurred in the course of the Group's marketing activities.

The Group's selling and distribution expenses increased by 0.1% from RMB115.5 million for the six months ended June 30, 2024 to RMB115.6 million for the six months ended June 30, 2025, remaining basically flat for both periods.

As a percentage of the revenue, the selling and distribution expenses decreased from 18.0% for the six months ended June 30, 2024 to 17.7% for the six months ended June 30, 2025.

## **Administrative Expenses**

During the Reporting Period, the Group's administrative expenses primarily consisted of (i) salaries and remuneration of administrative staff; (ii) consulting services fees, which include audit fees incurred with respect to engaging external auditors and IT service fees, and other service expenses procured to support corporate operations; (iii) transportation and travel expenses incurred in the course of administration and operations; and (iv) depreciation and amortization of non-current assets.

The Group's administrative expenses increased by 15.9% from RMB73.6 million for the six months ended June 30, 2024 to RMB85.3 million for the six months ended June 30, 2025, which was primarily attributable to the Group's active deployment of its R&D and production bases in recent years, with the establishment of the management team, and the recruitment expansion in related administrative departments, resulting in a corresponding increase in labor costs included in administrative expenses.

## **Finance Costs**

During the Reporting Period, the Group's finance costs primarily consisted of interest expenses on bank and other borrowings and lease liabilities. The Group's finance costs decreased by 49.0% from RMB20.6 million for the six months ended June 30, 2024 to RMB10.5 million for the six months ended June 30, 2025. Such decrease was mainly attributable to the gradual repayment of bank loans and other borrowings, and the continuous decline in interest rates on bank loans with floating interest rates during the Reporting Period, both resulting in a decrease in interest expenses.

## **Research and Development Expenses**

The Group closely followed the national strategic deployment, continuously increased investment in R&D projects, and strengthened independent innovation capabilities to ensure mid-to-long-term competitiveness. During the Reporting Period, the Group's research and development expenses increased by 23.6% from RMB35.1 million for the six months ended June 30, 2024 to RMB43.4 million for the six months ended June 30, 2025. This was mainly due to the continuous expansion of the Group's R&D team and the increased investment in the R&D of domestic products. As of the date of this announcement, the Group has successively obtained the medical device registration certificates for several self-developed products, including RGP of Suzhou Gaush Clear, two dry eye diagnostic devices, corneal confocal microscopes, ocular fundus cameras and frequency-domain biometer of Gaush Neotech, the intraocular lens implant system of Gaush Teleon, the disposable ophthalmic trocar and accessories of Gaush Precision, as well as the disposable ultrasonic emulsification vitrectomy irrigation-aspiration tubing kit and the corneal contact lens of Gaush Tech. The Group also develops a number of pipeline products, including optometric products, intraocular lenses, consumables of ultrasonic emulsification and diagnostic equipment of electrophysiology, all of which demonstrate the Group's long-term commitment to R&D investment.

## **Other Expenses**

During the Reporting Period, the Group's other expenses primarily consisted of asset impairment losses, credit impairment losses and exchange losses.

The Group's other expenses decreased from RMB12.0 million for the six months ended June 30, 2024 to RMB8.2 million for the six months ended June 30, 2025, which was mainly due to the decrease in exchange losses relating to amounts denominated in foreign currencies due to the fluctuation in foreign exchange rates.

## **Income Tax Expenses**

The Group's income tax expenses for the six months ended June 30, 2025 and 2024 both amounted to RMB31.5 million.

## **Profit for the Period**

For the foregoing reasons, the Group recorded a net profit of RMB35.9 million for the six months ended June 30, 2025 as compared to a net profit of RMB26.9 million for the six months ended June 30, 2024.

## **Financial Position**

### ***Financial Assets at Fair Value Through Profit or Loss***

The Group's financial assets at fair value through profit or loss represented funds purchased from certain financial institutions to improve cash utilization efficiency. The Group's financial assets at fair value through profit or loss decreased by 36.5% from RMB97.7 million as of December 31, 2024 to RMB62.0 million as of June 30, 2025. The relevant redemption plan was driven by the Group's ongoing efforts to improve capital management efficiency, actively seek high-return investment opportunities, and ensure the stable working capital for the Company's daily operations.

As of June 30, 2025, the Group's financial assets at fair value through profit or loss mainly include a private fund with a fair value of RMB60.5 million. The expected rate of return of such fund ranges from 2.5% to 4.5% per annum. As of the date of this announcement, the fund was fully redeemed.

## ***Inventories***

The Group's inventories consisted of finished goods, goods in transit, raw materials and work-in-progress. Under the inventory control policy, the Group regularly monitors and analyzes the Group's historical procurement, production and sales statistics and adjusts its inventories to meet the demand of customers in a timely manner without causing inventory accumulation. The Group's inventories increased by 8.1% from RMB334.4 million as of December 31, 2024 to RMB361.5 million as of June 30, 2025, primarily due to (i) the preparation in advance for the gradual launch and sale of self-developed products of domestic R&D and production companies; (ii) the new acquisition of two subsidiaries by Teleon; and (iii) the preparation in advance to counter the adverse impact of US tariff policies.

For the foregoing reasons, the Group's inventory turnover days increased from 163 days for the year ended December 31, 2024 to 193 days for the six months ended June 30, 2025. The inventory turnover days are calculated by dividing the arithmetic mean of the opening and ending carrying amount of inventories in that period by the cost of sales for the corresponding period and then multiplying by the number of days.

## ***Trade Receivables***

The Group's trade receivables represented outstanding amounts due from its customers. The Group's trade receivables increased by 3.3% from RMB170.9 million as of December 31, 2024 to RMB176.6 million as of June 30, 2025, remaining relatively flat for both periods.

The Group's trade receivable turnover days increased from 41 days for the year ended December 31, 2024 to 48 days for the six months ended June 30, 2025, which was mainly due to the increase in the balance of trade receivables as a result of the change in the customer structure, which led to an increase in the orders sold directly to end hospitals, whose settlement is usually on a payment after delivery basis. The Group's trade receivable turnover days were generally in line with the Group's credit term policies between 30 days and 90 days.

## ***Trade Payables***

The Group's trade payables primarily represented payments due to suppliers from whom imported the Distribution Products. The original value of the Group's trade payables decreased by 1.6% from RMB70.3 million as of December 31, 2024 to RMB69.2 million as of June 30, 2025, remaining relatively flat for both periods.

### ***Prepayments, Other Receivables and Other Assets***

The Group's prepayments, other receivables and other assets primarily consisted of (i) prepayments to suppliers; (ii) deposits that the Group paid to its customers as product quality assurance deposits; (iii) advance payment of income tax; and (iv) value-added tax recoverable, etc. The Group's prepayments, other receivables and other assets decreased by 4.8% from RMB163.3 million as of December 31, 2024 to RMB155.5 million as of June 30, 2025, primarily due to the decrease in prepayments for purchase of long-term assets.

### ***Goodwill***

Goodwill arose from acquisitions of the Group's subsidiaries, including Teleon and Rigeo B.V., of which, the carrying amounts of Teleon and Rigeo B.V. asset group were denominated in Euro. The Group's goodwill increased by 11.7% from RMB910.5 million as of December 31, 2024 to RMB1,016.6 million as of June 30, 2025, primarily attributable to the effect of fluctuation of exchange rate between RMB and Euro, and the acquisition of the intraocular lens business from Aracare Ltd., a Korean distributor.

### ***Intangible Assets***

The Group's intangible assets (other than goodwill) mainly represented the software the Group purchased and used in the ordinary course of business as well as the patents and trademarks identified as a result of business combinations, the development expenditures from capitalization of research and development expenses, and non-patented technology purchased and used for R&D project collaborations. The Group's intangible assets increased by 0.9% from RMB294.4 million as of December 31, 2024 to RMB297.1 million as of June 30, 2025, remaining relatively flat for both periods.

## **CAPITAL STRUCTURE, LIQUIDITY AND FINANCIAL RESOURCES**

The Shares were listed on the Main Board of the Stock Exchange on December 12, 2022. As of June 30, 2025, the issued share capital of the Company was USD14,789, and the number of issued Shares of USD0.0001 each was 147,887,869.

In the first half of 2025, the Group used internal resources to fund its liquidity. As the Group's business can generate stable cash inflow, together with abundant cash and bank balances, the Group has sufficient liquidity and financial resources to support its expansion plan. The Group regards monetary fund management as an essential part in financial management, and incorporates it to the key items of financial inspection and internal audit, and has continuously improved corresponding internal control management systems, including the "Monetary Fund Management System", to strengthen its monetary fund management, ensure the security of its monetary fund, and reduce the utilization costs and

financial risks of its monetary fund. As of June 30, 2025, the Group continued to maintain a solid financial position, with cash and cash equivalents balance amounting to RMB323.2 million, representing a decrease of 23.3% from RMB421.4 million as of December 31, 2024, primarily due to the repayment of domestic and overseas loans and interest amounting to approximately RMB149.7 million by the Group during the Reporting Period. The Group's cash is mainly in the form of bank deposit balances and deposited with reputable financial institutions and mature within one year. As of June 30, 2025, all cash and cash equivalents and term deposits of the Group were denominated in RMB, HKD, Euro and US dollars.

The Group's anticipated cash needs primarily include costs associated with the R&D of its products and business operations. The Group expects to fund its future working capital and other cash requirements with cash generated from its operations and, when necessary, bank and other borrowings.

The Group's interest-bearing bank and other borrowings represented guaranteed China Minsheng Bank loan and other guaranteed bank loans. As of June 30, 2025, the Group's interest-bearing bank and other borrowings amounted to RMB422.4 million, including current portion of RMB92.2 million and non-current portion of RMB330.2 million, all of which bore fixed interest rates, except for China Minsheng Bank loan. During the Reporting Period, the Company's main borrowings included the replacement loans granted by China Minsheng Bank. As of June 30, 2025, all of the Group's bank and other borrowings were denominated in Euro, USD and RMB.

## **Capital Expenditure**

The Group's capital expenditure for the six months ended June 30, 2025 amounted to RMB12.7 million as compared to that of RMB10.2 million for the six months ended June 30, 2024. The capital expenditure was primarily for the purchase of relevant production equipment by the Group to support the mass production and sales of multiple self-developed products.

## **Gearing Ratio**

Gearing ratio represented total interest-bearing borrowings divided by net assets or liabilities as of the end of the period and multiplied by 100%. Interest-bearing borrowings included interest-bearing bank and other borrowings and lease liabilities. As of June 30, 2025, the Group's gearing ratio was 28.0%. As of December 31, 2024, the Group's gearing ratio was 34.8%.

## **Pledge of Assets**

Except for the pledged assets mentioned in Note 13 to the financial statements as set out in this announcement, the Group had no other pledged assets as of June 30, 2025.

## **Contingent Liabilities**

As of June 30, 2025, the Group did not have any outstanding debt securities, mortgages, charges, debentures or other loan capital (issued or agreed to be issued), bank overdrafts, liabilities under acceptance or acceptance credits or other similar indebtedness, lease and finance lease commitments, hire purchase commitments, guarantees or other material contingent liabilities.

# **FINANCIAL RISKS**

## **Foreign Currency Risk**

Foreign currency risk is the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect the financial condition and results of operations of the Group. The Group purchases products from brand partners in many countries around the world. Therefore, the Group exposes to foreign currency risk when it enters into transactions denominated in multiple currencies. For example, changes in currency exchange rates may affect the Group's costs of goods sold and competitiveness against its domestic competitors or competitors who are multinational companies whose international operations provide a natural hedge to currency fluctuation risk. The Group predominantly purchases its products in US dollars and Euro. The Group sells the goods to distributors and hospitals and clinics in China in RMB. Given the Group's substantial receivables and payables denominated in US dollars or EUR, subject to the settlement cycle, fluctuations in foreign exchange rates during the cycle may lead to foreign exchange losses or gains. The Group's management will continue to pay attention to the Group's foreign exchange exposure and seeks to limit its exposure to foreign currency risk by minimizing its net foreign currency position. Exchange differences on translation of foreign operations represent the difference arising from the translation of the financial statements of companies within the Group that have a functional currency of Euro, which is different from the functional currency of RMB for the financial statements of the Company. For the six months ended June 30, 2025, the exchange differences on translation of foreign operations amounted to a gain of RMB100.0 million, primarily due to the fluctuation of exchange rate of Euro during the Reporting Period.

## **Credit Risk**

The Group trades on credit terms only with recognized and creditworthy third parties. It is the Group's policy that all traders who wish to trade on credit terms are subject to credit verification procedures. In addition, the Group monitors the receivable balances on an ongoing basis.

## **SIGNIFICANT INVESTMENT HELD**

As of June 30, 2025, the Group did not have any significant investment.

## **MATERIAL ACQUISITION AND DISPOSAL**

The Group had no material acquisition or disposal of subsidiaries, associates and joint ventures during the Reporting Period.

## **FUTURE PLANS FOR MATERIAL INVESTMENT AND CAPITAL ASSETS**

The Group did not have any future plans for material investment and capital assets as of the date of this announcement.

## **EMPLOYEES AND REMUNERATION POLICIES**

As of June 30, 2025, the Group had a total of 819 employees (as of December 31, 2024: 884). For the Reporting Period, the total costs for the Group's employees amounted to RMB192.1 million (for the six months ended June 30, 2024: RMB184.0 million). "Diligence and Capability" is the core value of the Group. The Group attaches great importance to employee competency development and continuously establishes a comprehensive training management system according to the Company's development needs. Through launching new employee induction training, general skills training for all positions, business training and external learning, the Group continuously deepens employees with professional and management knowledge and skills required for different fields, levels and positions, with an aim to help the employees achieve their career plan and development direction, effectively implement the overall strategic planning of human resources, and build sufficient talent reserves for the Group to achieve long-term high-quality development.

The Group adheres to the principles of fairness, justice and reasonable remuneration and provides its employees with competitive remuneration and benefits. The remuneration package of employees mainly includes basic salary and performance-based bonus. The performance targets of employees are primarily determined according to their positions and departments, and regular performance review will be conducted, and salaries, bonus and promotion appraisals will be determined based on appraisal results.

On August 28, 2024, the Company adopted a share award scheme (the “**Share Award Scheme**”) to recognize and reward eligible participants for their contribution to the Group, to attract best available personnel to provide service to the Group, and to provide additional incentives to them to remain with and further promote the success of the Group’s business. The Share Award Scheme is funded solely by existing Shares to be purchased by the trustee on the market. The Share Award Scheme constitutes a share scheme under Chapter 17 of the Listing Rules and shall be subject to the applicable disclosure requirements under Rule 17.12 of the Listing Rules. However, it does not constitute a scheme involving the issue of new Shares as referred to in Chapter 17 of the Listing Rules. From the adoption date of the Share Award Scheme to the date of this announcement, no awards have been granted, vested, cancelled or lapsed pursuant to the Share Award Scheme. For details, please refer to the announcement of the Company dated August 28, 2024.

## **SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD**

As of the date of this announcement, there was no subsequent event after the Reporting Period which has a material impact on the Group.

## **INTERIM DIVIDEND**

The Board did not recommend the payment of an interim dividend for the six months ended June 30, 2025 (six months ended June 30, 2024: Nil).

## **CORPORATE GOVERNANCE**

The Company is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as its own code of corporate governance. During the Reporting Period, the Company has, to the best knowledge of the Board, complied with all applicable code provisions of the CG Code.

The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

## **MODEL CODE FOR SECURITIES TRANSACTIONS**

The Company has adopted the Model Code as its own code of conduct regarding Directors' securities transactions. The Company has made specific enquiries of all the Directors, and each of the Directors has confirmed that he/she has complied with the required standards as set out in the Model Code during the Reporting Period.

During the Reporting Period, the Company has also adopted its own code of conduct regarding employees' securities transactions on terms no less exacting than the standard set out in the Model Code for the compliance by its relevant employees who are likely to be in possession of unpublished inside information of the Company in respect of their dealings in the Company's securities.

## **PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES**

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) during the Reporting Period. As of June 30, 2025, the Company did not hold any treasury shares.

## **AUDIT COMMITTEE**

The Company has established the Audit Committee with written terms of reference in compliance with the requirements under the Listing Rules. As at the date of this announcement, the Audit Committee comprises two independent non-executive Directors, namely, Mr. Chan Fan Shing and Mr. Feng Xin, and a non-executive Director, Dr. David Guowei Wang. The chairman of the Audit Committee is Mr. Chan Fan Shing. The primary functions of the Audit Committee are to review and supervise the financial reporting process, internal control and risk management system of the Group, oversee the audit process, provide advice and comments to the Board, perform other duties and responsibilities as may be assigned by the Board, and review and oversee the risk management of the Company.

The Audit Committee had, together with the management and external auditor of the Company, reviewed the accounting standards and practices adopted by the Group and the interim condensed consolidated financial statements of the Group for the six months ended June 30, 2025. The Audit Committee considered that the interim condensed consolidated financial statements of the Group for the six months ended June 30, 2025 are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

## **SCOPE OF WORK OF THE COMPANY'S AUDITOR**

The Group's interim condensed consolidated financial information for the six months ended June 30, 2025 is unaudited but has been reviewed by the Company's auditor, Ernst & Young, in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

## **PUBLICATION OF INTERIM RESULTS AND INTERIM REPORT**

This interim results announcement is published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.gaush.com](http://www.gaush.com)), and the interim report of the Company for the six months ended June 30, 2025 containing all the information required by the Listing Rules will be dispatched to the Shareholders and published on the respective websites of the Stock Exchange and the Company in due course.

The Board is pleased to announce the condensed consolidated interim results of the Group for the six months ended June 30, 2025 together with the comparative figures for the same period in 2024 as follows:

**INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS**

*For the six months ended 30 June 2025*

	<i>Notes</i>	<b>2025</b> (Unaudited) <i>RMB'000</i>	<b>2024</b> (Unaudited) <i>RMB'000</i>
<b>REVENUE</b>	4	<b>653,081</b>	642,034
Cost of sales		<b>(337,417)</b>	(343,681)
			<hr/>
Gross profit		<b>315,664</b>	298,353
Other income and gains		<b>14,689</b>	16,824
Selling and distribution expenses		<b>(115,593)</b>	(115,475)
Administrative expenses		<b>(85,277)</b>	(73,608)
Research and development expenses		<b>(43,400)</b>	(35,140)
Other expenses		<b>(8,178)</b>	(11,956)
Finance costs		<b>(10,549)</b>	(20,603)
		<hr/>	<hr/>
<b>PROFIT BEFORE TAX</b>	5	<b>67,356</b>	58,395
Income tax expense	6	<b>(31,462)</b>	(31,467)
		<hr/>	<hr/>
<b>PROFIT FOR THE PERIOD</b>		<b>35,894</b>	26,928
		<hr/>	<hr/>
Attributable to:			
Owners of the parent		<b>37,974</b>	28,474
Non-controlling interests		<b>(2,080)</b>	(1,546)
		<hr/>	<hr/>
		<b>35,894</b>	26,928
		<hr/>	<hr/>
<b>EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</b>	8		
Basic			
For profit for the period		<b>RMB0.26</b>	<b>RMB0.19</b>
		<hr/>	<hr/>
Diluted			
For profit for the period		<b>RMB0.26</b>	<b>RMB0.19</b>
		<hr/>	<hr/>

**INTERIM CONDENSED CONSOLIDATED STATEMENT OF  
COMPREHENSIVE INCOME**

*For the six months ended 30 June 2025*

	<b>2025</b> (Unaudited) <i>RMB'000</i>	2024 (Unaudited) <i>RMB'000</i>
<b>PROFIT FOR THE PERIOD</b>	<b><u>35,894</u></b>	<b><u>26,928</u></b>
<b>OTHER COMPREHENSIVE INCOME</b>		
<b>Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods</b>		
Exchange differences:		
Exchange differences on translation of foreign operations	<b><u>99,974</u></b>	<b><u>(19,818)</u></b>
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>	<b><u>135,868</u></b>	<b><u>7,110</u></b>
<b>Attributable to:</b>		
Owners of the parent	<b><u>137,948</u></b>	<b><u>8,656</u></b>
Non-controlling interests	<b><u>(2,080)</u></b>	<b><u>(1,546)</u></b>
	<b><u>135,868</u></b>	<b><u>7,110</u></b>

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2025

	Notes	30 June 2025 (Unaudited) <i>RMB'000</i>	31 December 2024 (Audited) <i>RMB'000</i>
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment		<b>88,195</b>	79,428
Right-of-use assets		<b>47,039</b>	44,584
Goodwill		<b>1,016,589</b>	910,506
Intangible assets		<b>297,067</b>	294,423
Long-term prepayments and other receivables		<b>35,756</b>	38,828
Deferred tax assets		<b>43,987</b>	47,765
 Total non-current assets		<b>1,528,633</b>	1,415,534
<b>CURRENT ASSETS</b>			
Financial assets at fair value through profit or loss	9	<b>61,969</b>	97,676
Inventories		<b>361,473</b>	334,419
Trade receivables	10	<b>171,472</b>	166,441
Contract assets		<b>1,097</b>	1,263
Prepayments, other receivables and other assets		<b>119,733</b>	124,498
Pledged deposits		<b>5,665</b>	5,042
Cash and cash equivalents	11	<b>323,187</b>	421,438
 Total current assets		<b>1,044,596</b>	1,150,777
<b>CURRENT LIABILITIES</b>			
Trade payables	12	<b>69,162</b>	70,344
Derivative financial instruments		<b>—</b>	538
Other payables and accruals		<b>137,761</b>	128,617
Tax payable		<b>10,480</b>	17,660
Interest-bearing bank and other borrowings	13	<b>92,165</b>	170,633
Contract liabilities		<b>107,745</b>	103,864
Lease liabilities		<b>18,240</b>	20,158
 Total current liabilities		<b>435,553</b>	511,814
<b>NET CURRENT ASSETS</b>			
 <b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>609,043</b>	638,963
		<b>2,137,676</b>	2,054,497

	<i>Notes</i>	<b>30 June 2025</b>	<b>31 December 2024</b>
		<b>(Unaudited)</b>	<b>(Audited)</b>
		<b>RMB'000</b>	<b>RMB'000</b>
<b>NON-CURRENT LIABILITIES</b>			
Government grant		<b>1,556</b>	1,801
Interest-bearing bank and other borrowings	13	<b>330,249</b>	337,095
Contract liabilities		<b>28,246</b>	29,856
Deferred tax liabilities		<b>58,591</b>	57,149
Other payables and accruals		<b>15,388</b>	16,059
Lease liabilities		<b>28,404</b>	24,350
		<hr/>	<hr/>
Total non-current liabilities		<b>462,434</b>	466,310
		<hr/>	<hr/>
<b>Net assets</b>		<b>1,675,242</b>	1,588,187
<b>EQUITY</b>			
Equity attributable to owners of the parent			
Share capital	14	<b>102</b>	102
Treasury shares		<b>(20,841)</b>	(11,688)
Reserves		<b>1,684,244</b>	1,586,725
		<hr/>	<hr/>
		<b>1,663,505</b>	1,575,139
		<hr/>	<hr/>
Non-controlling interests		<b>11,737</b>	13,048
		<hr/>	<hr/>
Total equity		<b>1,675,242</b>	1,588,187
		<hr/>	<hr/>

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2025

## 1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

The interim condensed consolidated financial information is presented in Renminbi (“RMB”) and all values are rounded to the nearest thousand (RMB'000) except when otherwise indicated.

## 2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended IFRS Accounting Standard for the first time for the current period's financial information.

Amendments to IAS 21                    *Lack of Exchangeability*

The nature and impact of the amended IFRS Accounting Standard are described below:

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

### 3. OPERATING SEGMENT INFORMATION

**Six months ended 30 June 2025**

	Proprietary products <i>RMB'000</i> (Unaudited)	Distribution products <i>RMB'000</i> (Unaudited)	Technical services <i>RMB'000</i> (Unaudited)	Others <i>RMB'000</i> (Unaudited)	Total <i>RMB'000</i> (Unaudited)
External sales	203,008	327,143	119,135	3,795	653,081
Intersegment sales	60,406	—	—	—	60,406
<b>Total segment revenue</b>	<b>263,414</b>	<b>327,143</b>	<b>119,135</b>	<b>3,795</b>	<b>713,487</b>
Elimination of intersegment sales					(60,406)
Segment revenue	203,008	327,143	119,135	3,795	653,081
Segment cost	75,387	203,182	58,568	280	337,417
Segment gross profit	127,621	123,961	60,567	3,515	315,664
<b>Six months ended 30 June 2024</b>					
	Proprietary products <i>RMB'000</i> (Unaudited)	Distribution products <i>RMB'000</i> (Unaudited)	Technical services <i>RMB'000</i> (Unaudited)	Others <i>RMB'000</i> (Unaudited)	Total <i>RMB'000</i> (Unaudited)
External sales	178,005	351,048	110,047	2,934	642,034
Intersegment sales	72,581	—	—	—	72,581
<b>Total segment revenue</b>	<b>250,586</b>	<b>351,048</b>	<b>110,047</b>	<b>2,934</b>	<b>714,615</b>
Elimination of intersegment sales					(72,581)
Segment revenue	178,005	351,048	110,047	2,934	642,034
Segment cost	84,371	197,367	61,206	737	343,681
Segment gross profit	93,634	153,681	48,841	2,197	298,353

## Geographical information

### (a) *Revenue from external customers*

	Six months ended 30 June	
	2025 <i>RMB'000</i> (Unaudited)	2024 <i>RMB'000</i> (Unaudited)
Greater China	<b>482,563</b>	497,129
Asia Pacific (excluding Greater China)	<b>33,150</b>	24,978
Germany	<b>100,442</b>	81,404
Europe (excluding Germany)	<b>20,671</b>	21,394
Americas (including Canada)	<b>7,782</b>	6,753
Oceania	<b>5,801</b>	8,172
Others	<b>2,672</b>	2,204
 Total	 <b>653,081</b>	 <b>642,034</b>

The revenue information above is based on the locations of the customers.

### (b) *Non-current assets*

	30 June 2025 <i>RMB'000</i> (Unaudited)	31 December 2024 <i>RMB'000</i> (Audited)
Greater China	<b>170,430</b>	178,699
Germany	<b>13,210</b>	12,694
Korea	<b>958</b>	—
Netherlands	<b>1,300,048</b>	1,174,591
 Total	 <b>1,484,646</b>	 <b>1,365,984</b>

The non-current asset information above is based on the locations of the assets and excludes financial instruments and deferred tax assets.

## 4. REVENUE

An analysis of revenue is as follows:

### Disaggregated revenue information for revenue from contracts with customers

#### Segments

	For the six months ended 30 June	
	2025 <i>RMB'000</i> (Unaudited)	2024 <i>RMB'000</i> (Unaudited)
<b>Types of goods or services</b>		
Sale of ophthalmic medical devices	<b>230,102</b>	273,009
Sale of ophthalmic medical consumables	<b>300,049</b>	256,044
Technical services*	<b>119,135</b>	110,047
Others	<b>3,795</b>	2,934
 Total	<b>653,081</b>	642,034
 <b>Geographical markets**</b>		
Greater China	<b>482,191</b>	496,770
Germany	<b>96,498</b>	72,950
Netherlands	<b>74,053</b>	72,314
Others	<b>339</b>	—
 Total	<b>653,081</b>	642,034
 <b>Timing of revenue recognition</b>		
Goods transferred at a point in time	<b>532,002</b>	531,140
Services transferred over time	<b>121,079</b>	110,894
 Total	<b>653,081</b>	642,034

\* Technical services include repair and maintenance services, which are either sold separately or bundled together with the sale of ophthalmic medical devices to customers.

\*\* Allocated by the geographical location of entities generating revenue.

## 5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<i><b>RMB'000</b></i>	<i><b>RMB'000</b></i>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Cost of inventories sold	<b>278,569</b>	281,738
Cost of services provided	<b>58,848</b>	61,943
 Cost of sales	 <b>337,417</b>	 <b>343,681</b>
 Foreign exchange losses, net	 <b>2,117</b>	 4,523
Impairment of trade receivables, net	<b>746</b>	773
Reversal of impairment of contract assets, net	<b>(3)</b>	(6)
Impairment of other receivables, net	<b>184</b>	94
(Reversal of write-down of)/write-down of inventories to net realisable value	<b>(4,256)</b>	5,135
(Gains)/losses on disposal of property, plant and equipment	<b>(5)</b>	97
Investment income from financial assets at fair value through profit or loss	<b>(1,577)</b>	(423)

## 6. INCOME TAX

### **Income tax for the Cayman Islands and the British Virgin Islands**

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands, the Group is not subject to any income tax in the Cayman Islands and the British Virgin Islands. In addition, upon payments of dividends by the Company and the subsidiaries incorporated in the British Virgin Islands to their shareholders, no withholding tax is imposed.

### **Hong Kong profits tax**

Hong Kong profits tax has been provided at the two-tiered profits tax rates on the estimated assessable profits arising in Hong Kong. The first HKD2,000,000 of assessable profits are taxed at 8.25% and the remaining assessable profits are taxed at 16.5%.

### **Corporate income tax for Mainland China**

Under the Law of the PRC on Corporate Income Tax (the “**CIT Law**”) and the Implementation Regulation of the CIT Law, the CIT rate for PRC subsidiaries is 25% except for those subsidiaries that are subject to tax exemption as set out below.

The Group’s subsidiary, Wenzhou Gaush Raymond Photoelectric Technology Co., Ltd., was accredited as a “High and New Technology Enterprise” in 2020 for a term of three years, and the certificate was reissued in December 2023 for a term of three years, therefore the subsidiary was entitled to a preferential CIT rate of 15% for the six months ended 30 June 2025.

For certain small low-profit PRC subsidiaries of the Group, the portion of the annual taxable income not exceeding RMB3,000,000 shall be computed at a reduced rate of 25% as the taxable income amount, and be subject to the CIT rate at 20%, which results in an effective tax burden of 5%.

## Income tax for other jurisdictions

The Group's tax provision in respect of other jurisdictions has been calculated at the applicable tax rates in accordance with the prevailing practices of the jurisdictions in which the Group operates.

Subsidiaries established in Germany were subject to corporate income tax at the rate of 15.825%. Furthermore, subsidiaries established in Germany were also subject to trade tax at trade tax rates of 14.35% and 15.75%, depending on the locations of the respective subsidiaries.

Subsidiaries established in the Netherlands were subject to corporate income tax at the rate of 19% for taxable income of EUR200,000 or less and at the rate of 25.8% for the portion exceeding EUR200,000. The management of the Group expects that Teleon Holding B.V., a subsidiary of the Company, together with its Dutch subsidiaries should qualify for the innovation box. A reduced tax rate of 9% applies to activities covered by the innovation box. The innovation box provides tax relief to encouraged innovative research. Qualifying profits earned from qualifying innovative activities are taxed at this special rate.

An analysis of the provision for tax in the interim condensed consolidated financial information is as follows:

	<b>For the six months ended 30 June</b>	
	<b>2025</b> <i>RMB'000</i> (Unaudited)	<b>2024</b> <i>RMB'000</i> (Unaudited)
Current — Hong Kong	<b>634</b>	9,639
Current — Mainland China	<b>21,093</b>	20,050
Current — Other jurisdictions	<b>9,294</b>	8,768
Deferred	<b>441</b>	(6,990)
 Total tax charge for the period	 <b><u>31,462</u></b>	 <b><u>31,467</u></b>

## 7. DIVIDENDS

The proposed final dividend of HKD0.30 per ordinary share of the Company for the year ended 31 December 2024 was declared payable by the shareholders of the Company at the annual general meeting of the Company on 29 May 2025.

No dividends have been declared and paid by the Company for the six months ended 30 June 2025 (six months ended 30 June 2024: Nil).

## 8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 146,000,506 (2024: 147,970,369) outstanding during the period.

No dilution issues effected the earnings per share attributable to ordinary equity holders of the parent for the six months ended 30 June 2025.

The calculations of basic and diluted earnings per share are based on:

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
<b>Earnings:</b>		
Profit attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculations	<b>37,974</b>	<b>28,474</b>

	<b>Number of shares</b>	
	<b>2025</b> <b>(Unaudited)</b>	<b>2024</b> <b>(Unaudited)</b>
<b>Shares:</b>		
Weighted average number of ordinary shares outstanding during the period, used in the basic earnings per share calculation*	<b>146,000,506</b>	147,970,369
<b>Total</b>	<b>146,000,506</b>	<b>147,970,369</b>

\* The weighted average number of shares was after taking into account the effect of treasury shares held.

## 9. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

	<b>30 June</b> <b>2025</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>31 December</b> <b>2024</b> <b>RMB'000</b> <b>(Audited)</b>
Subscription for investment in private funds*	<b>60,488</b>	97,554
Foreign exchange forward transaction	<b>1,481</b>	122
<b>Total</b>	<b>61,969</b>	<b>97,676</b>

\* The Group subscribed for relevant participating shares attributable to segregated portfolios. The subscribed private funds totalled RMB60,488,000 (equivalent to approximately USD8,000,000) with expected rates of return ranging from 2.5% to 4.5% per annum. The segregated portfolios seek to achieve the investment objective by investing in cash or cash equivalents, U.S. national debt and other money market instruments. The subscriptions of the above funds were approved by the board of directors and were mandatorily classified as financial assets at fair value through profit or loss as their contractual cash flows are not solely payments of principal and interest.

## 10. TRADE RECEIVABLES

	<b>30 June 2025</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>31 December 2024</b> <b>RMB'000</b> <b>(Audited)</b>
Trade receivables	<b>176,634</b>	170,857
Impairment	<b>(5,162)</b>	<b>(4,416)</b>
<b>Total</b>	<b><u>171,472</u></b>	<b><u>166,441</u></b>

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	<b>30 June 2025</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>31 December 2024</b> <b>RMB'000</b> <b>(Audited)</b>
Within 1 year	<b>153,900</b>	146,814
1 to 2 years	<b>12,921</b>	16,747
2 to 3 years	<b>4,255</b>	2,250
3 to 4 years	<b>387</b>	581
4 to 5 years	<b>9</b>	49
Over 5 years	—	—
<b>Total</b>	<b><u>171,472</u></b>	<b><u>166,441</u></b>

## 11. CASH AND CASH EQUIVALENTS

	<b>30 June 2025</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>31 December 2024</b> <b>RMB'000</b> <b>(Audited)</b>
Cash and bank balances	<b><u>323,187</u></b>	<b><u>421,438</u></b>

The Group's cash and cash equivalents were denominated in the following currencies:

	<b>30 June 2025 '000</b>	<b>31 December 2024 '000</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
RMB	<b>183,334</b>	241,333
USD	<b>13,579</b>	8,270
EUR	<b>10,854</b>	15,981
HKD	<b>6,976</b>	4,997

The RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, and Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash and cash equivalents earn interest at floating rates based on daily bank deposit rates or the specific rates in the agreement deposit contracts with banks. The bank balances are deposited with creditworthy banks with no recent history of default.

## 12. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of each reporting period, based on the invoice date, is as follows:

	<b>30 June 2025 <i>RMB'000</i></b>	<b>31 December 2024 <i>RMB'000</i></b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
Within 1 year	<b>67,878</b>	68,219
Over 1 year	<b>1,284</b>	2,125
 Total	<b><u>69,162</u></b>	<b><u>70,344</u></b>

### 13. INTEREST-BEARING BANK AND OTHER BORROWINGS

As at 30 June 2025			
	Effective interest rate (%)	Maturity	<i>RMB'000</i>
<b>Current</b>			
Bank loan – secured*	<b>Euribor+1</b>	<b>2026</b>	<b>57,268</b>
Bank loans – secured**	<b>2.70–5.16</b>	<b>2025</b>	<b>34,897</b>
 Total – current			<b><u>92,165</u></b>
<b>Non-current</b>			
Bank loan – secured*	<b>Euribor+0.7</b>	<b>2027</b>	<b>330,249</b>
 Total – non-current			<b><u>330,249</u></b>
 Total			<b><u>422,414</u></b>

\* The loan amounting to RMB387,517,000 (equivalent to EUR45,938,000) as at 30 June 2025 were guaranteed by the Company and pledged by 100% of shares of Gaush Coöperatief U.A., 100% of shares of Teleon Holding B.V., and the Company's debt service reserve account ("DSRA") balance in China Minsheng Banking Corp. Ltd Shanghai Pilot Free Trade Zone Branch (中國民生銀行股份有限公司上海自貿試驗區分行) ("Minsheng Bank") amounting to RMB5,665,000 (equivalent to EUR674,000).

The secured Minsheng Bank loan is subject to the following covenants that required to be tested half-yearly, at 30 June and 31 December.

- i) A leverage ratio does not exceed 3.50:1 as at 30 June 2025, which is calculated as total debt divided by EBITDA.
- ii) An interest cover ratio is not less than 4.00:1, which is calculated as EBITDA divided by finance costs.
- iii) A gearing ratio not exceed 0.6:1, which is calculated as total debt divided by net asset.

The Group considers there is no indication that it will have difficulties in complying with these covenants.

\*\* The loans from DBS Bank (China) Limited Beijing Branch (星展銀行(中國)有限公司北京分行), amounting to RMB14,081,000 as at 30 June 2025, were guaranteed by Gaus Medical Corporation and MingWang Medical Ltd with a maximum amount of USD6,853,000 or its equivalent in Euro. The loans from Citibank (China) Co., Ltd. Beijing Branch (花旗銀行(中國)有限公司北京分行), amounting to RMB20,816,000 as at 30 June 2025, were guaranteed by Global Vision Corporation, MingWang Medical Ltd. and Gaus Medical Corporation.

<b>31 December 2024</b>			
	<b>Effective interest rate</b>	<b>Maturity</b>	<b>RMB'000</b>
	(%)		
<b>Current</b>			
Bank loans – secured	3.90–5.16 Euribor+1	2025	79,384
Vendor loan – secured	7.00	2025	<u>91,249</u>
Total – current			<u>170,633</u>
<b>Non-current</b>			
Bank loans – secured	2025: Euribor+1 2026–2027: Euribor+0.7	2027	337,095
Total – non-current			<u>337,095</u>
Total			<u>507,728</u>

## 14. SHARE CAPITAL

### Shares

	<b>30 June 2025</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>31 December 2024</b> <b>RMB'000</b> <b>(Audited)</b>
Issued and fully paid:	<b><u>102</u></b>	<b><u>102</u></b>

A summary of movements in the Company's share capital is as follows:

	<b>Number of shares in issue</b>	<b>Share capital</b> <i>RMB'000</i>
At 1 January 2024 (Audited)	147,970,369	102
Cancellation of the shares (i)	<u>(82,500)</u>	<u>—</u>
At 31 December 2024 and 1 January 2025 (Audited)	<u>147,887,869</u>	<u>102</u>
At 30 June 2025 (Unaudited) (ii)	<u>147,887,869</u>	<u>102</u>

- (i) The Company purchased a total of 1,297,100 of its shares on the Hong Kong Stock Exchange. As at 31 December 2024, the Group had 1,214,600 purchased shares classified as treasury shares held for the share award scheme in the future.
- (ii) The Company purchased a total of 1,347,200 of its shares on the Hong Kong Stock Exchange from 1 January 2025 to 30 June 2025. As at 30 June 2025, the Group had 2,561,800 purchased shares classified as treasury shares held for the share award scheme in the future.

## DEFINITIONS AND GLOSSARIES

In this announcement, the following expressions have the meanings set out below unless the context otherwise requires:

“associates”	has the meaning ascribed to it under the Listing Rules
“Audit Committee”	the audit committee of the Company
“Board”	the board of Directors
“cataract”	a dense, cloudy area that forms in the lens of the eye which begins when proteins in the eye form clumps that prevent the lens from sending clear images to the retina
“CG Code”	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
“China” or “PRC”	the People’s Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires otherwise, references herein to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan
“Companies Ordinance”	the Companies Ordinance, Chapter 622 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
“Company”	Gaush Meditech Ltd 高视医疗科技有限公司, an exempted company incorporated under the laws of the Cayman Islands with limited liability on November 1, 2017, the Shares of which are listed on the Main Board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“Distribution Products”	products of the brand partners which the Group distributes
“EUR” or “Euro”	the lawful currency of the European Union
“electrophysiological equipment”	electrophysiological equipment uses an objective and non-invasive diagnostic technique, which can evaluate visual disorder by measuring electrical signals produced by the visual system

“Gaush Neotech”	Gaush Neotech Ltd* (高視創新科技有限公司), a company with limited liability incorporated under the laws of the PRC on February 15, 2023 and an indirect wholly-owned subsidiary of the Company
“Gaush Precision”	Gaush Precision Ltd* (高視精密醫療器械(蘇州)有限公司), a company with limited liability incorporated under the laws of the PRC on May 10, 2018 and an indirect subsidiary of the Company, in which the Company holds 85.00% equity interest
“Gaush Tech”	Gaush Tech Ltd* (深圳高視科技有限公司), a company with limited liability incorporated under the laws of the PRC on January 6, 2022 and an indirect wholly-owned subsidiary of the Company
“Gaush Teleon”	Gaush Teleon Ltd* (高視泰靚醫療科技有限公司), a company with limited liability incorporated under the laws of the PRC on June 22, 2021 and an indirect wholly-owned subsidiary of the Company
“glaucoma”	a group of eye diseases that are usually characterized by progressive structural and functional changes of the optic nerve, which is caused by fluid building up in the front part of the eye
“Greater China”	for the purposes of this announcement and for geographical reference only, the Chinese Mainland, Hong Kong, Macau and Taiwan
“Group” or “Gaush”	the Company and all of its subsidiaries
“HK\$” or “HKD”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“IFRS”	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
“intraocular lens”	an artificial replacement for the lens of human eye removed during cataract surgery
“KOL”	key opinion leaders, being physicians with influence on their peers' medical practice for the purpose of this announcement

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the GEM of the Stock Exchange
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
“NMPA”	National Medical Products Administration (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局)
“OK-Lens”	orthokeratology lenses, also known as orthokeratology, is a non-surgical method to eliminate the refractive error of the eye and improve the naked vision by changing the geometry of the cornea within the pressure of the eyelids during sleep which is placed on the upper surface of the cornea when wearing
“Proprietary Products”	products that the Group develops and manufactures
“refractive error”	eye disorder caused by irregularity in the shape of the eye, which makes it difficult for the eyes to focus images clearly
“R&D”	research and development
“Reporting Period”	the six months ended June 30, 2025
“RGP”	rigid gas permeable corneal contact lenses
“RMB”	Renminbi, the lawful currency of the PRC
“Roland”	Roland Consult Stasche & Finger GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) duly incorporated under the laws of Germany and founded on November 29, 1995 and an indirect subsidiary of the Company, in which the Company holds 80.00% equity interest
“Share(s)”	ordinary share(s) in the share capital of the Company with a par value of US\$0.0001 each
“Shareholder(s)”	holder(s) of the Share(s)

“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed thereto under Section 15 of the Companies Ordinance
“Suzhou Gaush Clear”	Gaush Clear Ltd* (蘇州高視高清醫療技術有限公司), a company with limited liability incorporated under the laws of the PRC on February 24, 2021 and an indirect subsidiary of the Company, in which the Company holds 80.00% equity interest
“Teleon”	Teleon Holding B.V., an indirect wholly-owned subsidiary of the Company acquired in January 2021, and its subsidiaries
“treasury share(s)”	has the meaning ascribed to it under the Listing Rules
“United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US dollars”, “USD” or “US\$”	United States dollars, the lawful currency of the United States
“vitreoretinal diseases”	diseases that develop from the back surface of the eye and the vitreous fluid around it, with the most representative vitreoretinal diseases being wet age-related macular degeneration (wAMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV)
“%”	per cent

By order of the Board  
**Gaush Meditech Ltd**  
**Mr. Gao Tieta**

*Chairman and Executive Director*

Hong Kong, August 28, 2025

*As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.*

\* For identification purposes only